FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents

The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for MRI.
ReachMD Healthcare Image
Media formats available
  • Completing the pre-test is required to access this content.
    Pre-Survey
    Completing the pre-survey is required to access this content.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free